Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

868236

registered interest
date	20/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they intend to ensure that the FreeStyle Libre flash glucose monitoring system is accessible to all diabetes patients who would benefit from it.
tabling member printed	Lord Morris of Aberavon
uin	HL6508
answer	answer is ministerial correction date of answer 05/04/2018 answer text <p>The flash glucose testing monitoring system known as the Freestyle Libre was approved for reimbursement on National Health Service prescription from 1 November 2017 through its listing in Part IX of the NHS England and Wales Drug Tariff.</p><p>The listing of a medical device in the Drug Tariff should not be interpreted as a recommendation to prescribe a particular product. Flash glucose testing is not suitable for everyone. The Regional Medicines Optimisation Committee has issued advice on the use of Freestyle Libre to support decisions about its use. Patients will need to discuss the ongoing management of their condition with their healthcare professional and consider whether flash glucose monitoring is suitable for them.</p><p>The Department has no plans to ask clinical commissioning groups (CCGs) to review their prescribing policies or monitor access to flash glucose monitoring.</p><p>Within its financial constraints, the NHS is committed to providing access to new drugs and medical technologies. Ultimately it is for CCGs, who are primarily responsible for commissioning diabetes services, to meet the requirements of their population. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population, are based on the available evidence and take into account national guidelines. This includes determining whether specific technologies, such as flash glucose monitoring, form part of their service and if it is suitable for individual patients to support the ongoing management of their condition.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL6509 HL6510 HL6511 question first answered 05/04/2018 12:21:56 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	565 label Biography information for Lord Morris of Aberavon

868237

registered interest
date	20/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the effect of flash glucose monitoring on the management of diabetes.
tabling member printed	Lord Morris of Aberavon
uin	HL6509
answer	answer is ministerial correction date of answer 05/04/2018 answer text <p>The flash glucose testing monitoring system known as the Freestyle Libre was approved for reimbursement on National Health Service prescription from 1 November 2017 through its listing in Part IX of the NHS England and Wales Drug Tariff.</p><p>The listing of a medical device in the Drug Tariff should not be interpreted as a recommendation to prescribe a particular product. Flash glucose testing is not suitable for everyone. The Regional Medicines Optimisation Committee has issued advice on the use of Freestyle Libre to support decisions about its use. Patients will need to discuss the ongoing management of their condition with their healthcare professional and consider whether flash glucose monitoring is suitable for them.</p><p>The Department has no plans to ask clinical commissioning groups (CCGs) to review their prescribing policies or monitor access to flash glucose monitoring.</p><p>Within its financial constraints, the NHS is committed to providing access to new drugs and medical technologies. Ultimately it is for CCGs, who are primarily responsible for commissioning diabetes services, to meet the requirements of their population. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population, are based on the available evidence and take into account national guidelines. This includes determining whether specific technologies, such as flash glucose monitoring, form part of their service and if it is suitable for individual patients to support the ongoing management of their condition.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL6508 HL6510 HL6511 question first answered 05/04/2018 12:21:56 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	565 label Biography information for Lord Morris of Aberavon

868238

registered interest
date	20/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether there are plans to encourage Clinical Commissioning Groups to review their policies on prescribing flash glucose monitoring systems to those with type 1 diabetes on the NHS.
tabling member printed	Lord Morris of Aberavon
uin	HL6510
answer	answer is ministerial correction date of answer 05/04/2018 answer text <p>The flash glucose testing monitoring system known as the Freestyle Libre was approved for reimbursement on National Health Service prescription from 1 November 2017 through its listing in Part IX of the NHS England and Wales Drug Tariff.</p><p>The listing of a medical device in the Drug Tariff should not be interpreted as a recommendation to prescribe a particular product. Flash glucose testing is not suitable for everyone. The Regional Medicines Optimisation Committee has issued advice on the use of Freestyle Libre to support decisions about its use. Patients will need to discuss the ongoing management of their condition with their healthcare professional and consider whether flash glucose monitoring is suitable for them.</p><p>The Department has no plans to ask clinical commissioning groups (CCGs) to review their prescribing policies or monitor access to flash glucose monitoring.</p><p>Within its financial constraints, the NHS is committed to providing access to new drugs and medical technologies. Ultimately it is for CCGs, who are primarily responsible for commissioning diabetes services, to meet the requirements of their population. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population, are based on the available evidence and take into account national guidelines. This includes determining whether specific technologies, such as flash glucose monitoring, form part of their service and if it is suitable for individual patients to support the ongoing management of their condition.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL6508 HL6509 HL6511 question first answered 05/04/2018 12:21:56 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	565 label Biography information for Lord Morris of Aberavon

868239

registered interest
date	20/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they intend to monitor access to flash glucose monitoring to ensure its availability in all areas of England.
tabling member printed	Lord Morris of Aberavon
uin	HL6511
answer	answer is ministerial correction date of answer 05/04/2018 answer text <p>The flash glucose testing monitoring system known as the Freestyle Libre was approved for reimbursement on National Health Service prescription from 1 November 2017 through its listing in Part IX of the NHS England and Wales Drug Tariff.</p><p>The listing of a medical device in the Drug Tariff should not be interpreted as a recommendation to prescribe a particular product. Flash glucose testing is not suitable for everyone. The Regional Medicines Optimisation Committee has issued advice on the use of Freestyle Libre to support decisions about its use. Patients will need to discuss the ongoing management of their condition with their healthcare professional and consider whether flash glucose monitoring is suitable for them.</p><p>The Department has no plans to ask clinical commissioning groups (CCGs) to review their prescribing policies or monitor access to flash glucose monitoring.</p><p>Within its financial constraints, the NHS is committed to providing access to new drugs and medical technologies. Ultimately it is for CCGs, who are primarily responsible for commissioning diabetes services, to meet the requirements of their population. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population, are based on the available evidence and take into account national guidelines. This includes determining whether specific technologies, such as flash glucose monitoring, form part of their service and if it is suitable for individual patients to support the ongoing management of their condition.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL6508 HL6509 HL6510 question first answered 05/04/2018 12:21:56 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	565 label Biography information for Lord Morris of Aberavon